Bacoside A downregulates matrix metalloproteinases 2 and 9 in DEN-induced hepatocellular carcinoma

Cell Biochemistry and Function

Volumn 28, Issue 2, 2010, Pages 164-169

  Janani, Panneerselvam ^a   Sivakumari, Kanakarajan ^a   Geetha, Arumugam ^b   Yuvaraj, Sambandam ^c   Parthasarathy, Chandrakesan ^c  

^a PRESIDENCY COLLEGE   (India)

^b BHARATHI WOMEN S COLLEGE   (India)

^c UNIVERSITY OF MADRAS   (India)

Author keywords

Bacoside A; Hepatocelluar carcinoma; MMP 2; MMP 9; N nitroso diethylamine

Indexed keywords

BACOSIDE A; CARCINOGEN; DIETHYLNITROSAMINE; GELATIN; GELATINASE A; GELATINASE B; TRITERPENOID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; IMMUNOBLOTTING; LIVER CELL CARCINOMA; LIVER PROTECTION; MALE; NONHUMAN; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR DOWN REGULATION; ZYMOGRAPHY;

ANIMALS; DIETHYLNITROSAMINE; DOWN-REGULATION; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; RATS; RATS, WISTAR; SAPONINS; TRITERPENES;

RATTUS;

EID: 77249140494     PISSN: 02636484     EISSN: 10990844     Source Type: Journal    
DOI: 10.1002/cbf.1638     Document Type: Article

References (68)

1. Qin LX, Tang ZY. Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature. J Cancer Res Clin Oncol 2004; 130: 497-513.
2. Christofori G. New signals from the invasive front. Nature 2006; 441: 444-450.
3. Huang S, Mills L, Mian B, et al. Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am J Pathol 2002; 161: 125-134.
4. Hofmann UB, Eggert AA, Blass K, Bröcker EB, Becker JC. Stromal cells as the major source for matrix metalloproteinase-2 in cutaneous melanoma. Arch Dermatol Res 2005; 297: 154-160.
5. Hojilla CV, Mohammed FF, Khokha R. Matrix metalloproteinases and their tissue inhibitors direct cell fate during cancer development. Br J Cancer 2003; 89: 1817-1821.
6. Stetler-Stevenson WG, Liotta LA, Kleiner DE Jr. Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis. FASEB J 1993; 7: 1434-1441.
7. Bergers G, Javaherian K, Lo K, Folkman J, Hanahan D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 1999; 284: 808-812.
8. Coussens ML, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002; 295: 2387-2392.
9. Bernhard EJ, Gruber SB, Musche RJ. Direct evidence linking expression of matrix metalloproteinase 9 (92-kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells. Proc Natl Acad Sci U S A 1994; 91: 4293-4297.
10. Kawamata H, Kameyama S, Kawai K, et al. Marked acceleration of the metastatic phenotype of a rat bladder carcinoma cell line by the expression of human gelatinase A. Int J Cancer 1995; 63: 568-575.
11. Lyons JG, Birkedal-Hansen B, Moore WG, Harber G, Birkedal-Hansen H. Mr 95,000 metalloproteinase produced by rat mammary epithelial cells. Matrix Suppl 1992; 1: 85-86.
12. Matrisian LM, McDonnell S, Miller DB, Navre M, Seftor EA, Hendrix MJ. The role of the matrix metalloproteinase stromelysin in the progression of squamous cell carcinomas. Am J Med Sci 1991; 302: 157-162.
13. Sato H, Kida Y, Mai M, et al. Expression of genes encoding type IV collagen-degrading metalloproteinases and tissue inhibitors of metalloproteinases in various human tumor cells. Oncogene 1992; 7: 77-83.
14. Tsunezuka Y, Kinoh H, Takino T, et al. Expression of membrane-type matrix metallo proteinase 1 (MT1-MMP) in tumor cells enhances pulmonary metastasis in an experimental metastasis assay. Cancer Res 1996; 56: 5678-5683.
15. Bonfil RD, Medina PA, Gomez DE, et al. Expression of gelatinase/type IV collagenase in tumor necrosis correlates with cell detachment and tumor invasion. Clin Exp Metastasis 1992; 10: 211-220.
16. Sreenath T, Matrisian LM, Stetler-Stevenson W, Gattoni-Celli S, Pozzatti RO. Expression of matrix metalloproteinase genes in transformed rat cell lines of high and low metastatic potential. Cancer Res 1992; 52: 4942-4947.
17. Powell WC, Knox JD, Navre M, et al. Expression of the metalloproteinase matrilysin in DU-145 cells increases their invasive potential in severe combined immunodeficient mice. Cancer Res 1993; 53: 417-422.
18. Hou L, Li Y, Jia YH, et al. Molecular mechanism about lymphogenous metastasis of hepatocarcinoma cells in mice. World J Gastroenterol 2001; 7: 532-536.
19. Liabakk NB, Talbot I, Smith RA, Wilkinson K, Balkwill F. Matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer. Cancer Res 1996; 56: 190-196.
20. Chandler S, Miller KM, Clements JM, et al. Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview. J Neuroimmunol 1997; 72: 155-161.
21. Sawada S, Murakami K, Yamaura T, Mitani N, Tsukada K, Saiki I. Therapeutic and analysis model of intrahepatic metastasis reflects clinical behavior of hepatocellular carcinoma. Jpn J Cancer Res 2002; 93: 190-197.
22. Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 2001; 93: 178-193.
23. Taras D, Blanc JF, Rullier A, et al. Pravastatin reduces lunch metastasis of rat hepatocellular carcinoma via a coordinated decrease of MMP expression and activity. J Hepatol 2007; 46: 69-76.
24. Zhang D, Bar-Eli M, Meloche S, Brodt P. Dual regulation of MMP-2 expression by the type 1 insulin-like growth factor receptor: the phosphatidylinositol 3-kinase/Akt and Raf/ERK pathways transmit opposing signals. J Biol Chem 2004; 79: 19683-19690.
25. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
26. Paraskevi A, Ronald A. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006; 6: 1-14.
27. Ahmedin Jemal DVM, Rebecca Siegel MPH, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43-66.
28. Wild CP, Montesano R. A model of interaction: aflatoxins and hepatitis viruses in liver cancer aetiology and prevention. Cancer Lett 2009; 286: 22-28.
29. Pitot HC, Sirica AE. The stage of initiation and promotion in hepatocarcinogenesis. Biochem Biophys Acta 1980; 605: 191-215.
30. Mise M, Arii S, Higashituji H, et al. Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor. Hepatology 1996; 23: 455-464.
31. Mitsuhashi N, Shimizu H, Ohtsuka M, et al. Angiopoietins and Tie-2 expression in angiogenesis and proliferation of human hepatocellular carcinoma. Hepatology 2003; 37: 1105-1113.
32. Yoshiji H, Kuriyama S, Yoshii J, et al. Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma. Hepatology 2002; 35: 834-842.
33. Sun MH, Han XC, Jia MK, et al. Expressions of inducible nitric oxide synthase and matrix metalloproteinase-9 and their effects on angiogenesis and progression of hepatocellular carcinoma. World J Gastroenterol 2005; 11: 5931-5937.
34. Ishii Y, Nakasato Y, Kobayashi S, Yamazaki Y, Aoki T. A study on angiogenesis-related matrix metalloproteinase networks in primary hepatocellular carcinoma. J Exp Clin Cancer Res 2003; 22: 461-470.
35. Taraphdar AK, Roy M, Bhattacharya RK. Natural products as inducers of apoptosis: implication for cancer therapy and prevention. Curr Sci 2001; 80: 1387-1396.
36. Singh HK, Rastogi RP, Srimal RC, Dhawan BN. Effect of bacosides A and B on avoidance responses in rats. Phytother Res 1988; 2: 70-75.
37. Singh HK, Dhawan BN. Effect of Bacopa monniera Linn. (brahmi) extract on avoidance responses in rat. J Ethnopharmacol 1982; 5: 205-214.
38. Pawar R, Gopalakrishnan C, Bhutani KK. Dammarane triterpene saponin from Bacopa monniera as the superoxide inhibitor in polymorphonuclear cells. Planta Med 2001; 67: 752-754.
39. D'souza P, Deepak M, Rani P, et al. Brine shrimp lethality assay of Bacopa monnieri. Phytother Res 2002; 16: 197-198.
40. Nadkarni KM. In Indian Materia Medica, Vol I. Popular Prakashan Pvt Ltd.: Bombay, India, 1976; 624-625.
41. Bhakuni DS, Dhar ML, Dhar MM, Dhawan BNS, Mehrotra BN. Screening of Indian medicinal plants for biological activity. Part II. Indian J Exp Biol 1969; 7: 250-262.
42. Elangovan V, Govindasamy S, Ramamoorthy N, Balasubramanian K. In vitro studies on the anticancer activity of Bacopa monnieri. Fitoterapia 1995; 66: 211-215.
43. Janani P, Sivakumari K, Parthasarathy C. Hepatoprotective activity of bacoside A against N-nitrosodiethylamine-induced liver toxicity in adult rats. Cell Biol Toxicol 2009; 25: 425-434.
44. Deepak M, Sangli GK, Arun PC, Amit A. Quantitative determination of the major saponin mixture bacoside A in Bacopa monnieri by HPLC. Phytochem Anal 2005; 16: 24-29.
45. Ha WS, Kim CK, Sung SH, Kang CB. Study on the mechanism of multistep hepatotumorigenesis in rat: development of hepatotumorigenesis. J Vet Sci 2001; 2: 53-58.
46. Nalbandian A, Djakiew D. The p75(NTR) metastasis suppressor inhibits urokinase plasminogen activator, matrix metalloproteinase-2 and matrix metalloproteinase-9 in PC-3 prostate cancer cells. Clin Exp Metastasis 2006; 23: 107-116.
47. Werb Z. ECM and cell surface proteolysis: regulating cellular ecology. Cell 1997; 91: 439-442.
48. Chiarugi V, Ruggiero M, Magnelli L. Molecular polarity in endothelial cells and tumor-induced angiogenesis. Oncol Res 2000; 12: 1-4.
49. Hiratsuka S, Nakamura K, Iwai S, et al. MMP-9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2002; 2: 289-300.
50. Egeblad M,Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2: 161-174.
51. Forget MA, Desrosiers RR, Beliveau R. Physiological roles of matrix metalloproteinases: implications for tumor growth and metastasis. Can J Physiol Pharmacol 1999; 77: 465-480.
52. Thomas GT, Lewis MP, Speight PM. Matrix metalloproteinases and oral cancer. Oral Oncol 1999; 35: 227-233.
53. Duffy MJ, Maguire TM, Hill A, McDermott E, O'Higgins N. Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res 2000; 2: 252-257.
54. Morgia G, Falsaperla M, Malaponte G, et al. Matrix metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2, MMP-9) markers of prostate cancer. Urol Res 2005; 33: 44-50.
55. Stetler-Stevenson WG. The role of matrix metalloproteinases in tumor invasion, metastasis, and angiogenesis. Surg Oncol Clin NAm 2001; 10: 383-392.
56. Klein G, Vellenga E, Fraaije MW, Kamps WA, De Bont ES. The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g., acute leukemia. Crit Rev Oncol Hematol 2004; 50: 87-100.
57. Mook OR, Frederiks WM, Van Noorden CJ. The role of gelatinases in colorectal cancer progression and metastasis. Biochim Biophys Acta 2004; 1705: 69-89.
58. Schmalfeldt B, Prechtel D, Härting K, et al. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benigh to advanced ovarian cancer. Clin Cancer Res 2001; 7: 2396-2404.
59. Bérubé M, Deschambeault A, Boucher M, Germain L, Petitclerc E, Guérin SL. MMP-2 expression in uveal melanoma: differential activation status dictated by the cellular environment. Mol Vis 2005; 11: 1101-1111.
60. Lee KJ, Hwang SJ, Choi JH, Jeong HG. Saponins derived from the roots of Platycodon grandiflorum inhibit HT-1080 cell invasion and MMPs activities: regulation of NF-kappaB activation via ROS signal pathway. Cancer Lett 2008; 268: 233-243.
61. Liotta LA, Steeg PS, Stetler-stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991; 64: 327-336.
62. Choo MK, Sakurai H, Kim DH, Saiki I. A ginseng saponin metabolite suppresses tumor necrosis factor-alpha-promoted metastasis by suppressing nuclear factor-kappaB signaling in murine colon cancer cells. Oncol Rep 2008; 19: 595-600.
63. Bharti AC, Aggarwal BB. Chemopreventive agents induce suppression of nuclear factor-kappaB leading to chemosensitization. Ann N Y Acad Sci 2002; 973: 392-395.
64. Greten FR, Eckmann L, Greten TF, et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004; 118: 285-296.
65. Wang WH, Huang JQ, Zheng GF, Lam SK, Karlberg J, Wong BC. Nonsteroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic reviewandmeta-analysis. JNatlCancer Inst 2003; 95: 1784-1791.
66. Garber K. Aspirin for cancer chemoprevention: still a headache? J Natl Cancer Inst 2004; 96: 252-253.
67. Ness RB, Cottreau C. Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst 1999; 91: 1459-1467.
68. Chang ET, Zheng T, Weir EG, et al. Aspirin and the risk of Hodgkin's lymphoma in population-based case-control study. J Natl Cancer Inst 2004; 96: 305-315.